Workflow
OJEMDA™ (tovorafenib)
icon
Search documents
Day One Biopharmaceuticals pany(DAWN) - 2025 Q1 - Earnings Call Presentation
2025-05-06 20:33
First Quarter 2025 Financial Results & Corporate Progress MAY 2025 Forward looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as "m ...
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
Newsfilter· 2025-04-14 11:30
XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, annou ...